Global Oral Cavity Cancer Market - 2024-2031

Oral Cavity Cancer Market Size

The Global Oral Cavity Cancer Market reached US$ 1.92 billion in 2023 and is expected to reach US$ 2.94 billion by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Oral carcinoma is a tumor that develops in the mouth or throat tissues. Belonging to a more extensive group of cancers called head and neck cancers. Commonly develops in the squamous cells in the mouth, tongue, and lips.

Oral Cavity Cancer Market Dynamics

The growing cases of oral cancer, increased tobacco consumption, growing geriatric population, and increased research and development for oral cavity cancer are fueling the growth of the global oral cavity cancer market during the forecast period.

The increasing research and development on oral cancer treatment are boosting the growth of the global oral cavity cancer market.

The increasing research activities on oral cavity cancer will fuel the global oral cavity cancer market growth during the forecast period. According to clinicaltrial.gov, over 126 clinical studies are currently active on oral cavity cancer. Examples of a few are a phase II study evaluating the efficacy of Nivolumab in combination with Ipilimumab in patients with recurrent and/or metastatic (R/M) salivary gland cancers (SGCs), the Memorial Sloan Kettering Cancer Center sponsors the study collaborated with Bristol-Myers Squibb and estimated to be completed by May 2023. Another open-label Phase 2 study to evaluate the efficacy and safety of Apalutamide in combination with gonadotropin-releasing hormone (GnRH) agonist in subjects with locally advanced or recurrent/metastatic and androgen receptor (AR) expressing salivary gland carcinoma study is sponsored by Janssen Pharmaceutical K.K. and expected to be finished by May 2023.

Also, a phase I trial of Bevacizumab, Temsirolimus alone and in combination with Valproic Acid, or Cetuximab in patients with advanced malignancies and other indications such as lip and oral cavity carcinoma and others, the study is estimated to be finished by March 2023 and is sponsored by M.D. Anderson Cancer Center in collaboration with National Cancer Institute (NCI). Thus, the above data indicate that the increased clinical research on oral cavity cancer is boosting the global oral cavity cancer market growth during the forecast period.

The high treatment cost and risk of recurrence restrain the growth of the global oral cavity cancer market.

However, insufficient awareness of oral cancer in backward and underdeveloped areas, high costs of the treatment and the risk of recurrence even after the treatment will also hamper the market growth rate will hamper the global oral cavity cancer market growth during the forecast period. For instance, the Cost of radiation therapy for mouth cancer in India is around $9,000 - $12,890. As per a research report published by the Department of Head and Neck Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, India, in 2022, over half of the patients with oral cancer recur even after multimodality treatment and recurrent oral cancers carry a poorer prognosis when compared to other sites of head and neck.

COVID-19 Impact on Oral Cavity Cancer Market

The COVID-19 pandemic has greatly affected the global oral cavity cancer market growth as there were changes in the risk factor for oral cancer. For instance, the development of oral cancer has been linked to tobacco and alcohol use, poor diet and nutrition, excess body weight, human papillomavirus (HPV) infection, poor oral hygiene, and male sex. Research reveals that tobacco use, alcohol consumption, and obesity rates have increased considerably during the COVID-19 pandemic. These risk factors, in addition, are implicated in an increased risk of experiencing COVID-19-related mortality, thereby leading to increases in oral cancer cases. Thus, positively impacting the global oral cavity cancer market growth.

Oral Cavity Cancer Market Segment Analysis

Squamous cell carcinoma is assumed to command the global market throughout the forecast period (2023-2030).

Squamous cell carcinoma is expected to dominate the global oral cavity cancer market throughout the forecast period (2022-2029) owing to the high prevalence of squamous cell carcinoma and many active interventional clinical trials. According to the Memorial Sloan Kettering Cancer Center, squamous cells are thin, flat cells that look like fish scales and are found in the tissue that forms the skin's surface, the lining of the body's hollow organs, and the lining of the respiratory and digestive tracts. Also, over 90 percent of mouth cancers are squamous cell carcinoma.

Furthermore, many interventional clinical studies are active on squamous cell oral cancer, fueling squamous cell carcinoma's dominance over the global oral cavity carcinoma market during the forecast period. For instance, a phase-2 trial for a multimodality therapy with induction Carboplatin/Nab-Paclitaxel/Durvalumab followed by surgical resection and risk-adapted adjuvant therapy for the treatment of locally-advanced and surgically resectable squamous cell carcinoma of the head and neck, sponsored by UNC Lineberger Comprehensive Cancer Center in collaboration with AstraZeneca Celgene and is estimated to be finished by December 2026. Also, a Single-arm Phase I Trial for the Treatment of Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma with Camrelizumab and Apatinib is expected to be completed by December 2023 and is sponsored by Shanghai Jiao Tong University School of Medicine. Therefore, from the mentioned data, it is estimated that squamous cell carcinoma will dominate the global oral cavity cancer market during the forecast period.

Oral Cavity Cancer Market Geographical Share

The North American region holds the largest global oral cavity cancer market.

North America is predicted to be holding a larger share of the global oral cavity cancer market during the forecast period (2022-2029) since the majority of key market players such as Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc. and Cipla Inc. which are holding a large share of the global oral cavity cancer market are U.S based. Furthermore, the presence of various government and non-government organizations such as spreading awareness about oral cancer such as the Prevent Cancer Foundation, American Cancer Association, American Cancer Society, The Oral Cancer Foundation - Head & Neck Cancer and much more spreading awareness about oral cavity cancer in North America fuels this regions dominance over the global oral cavity cancer market.

In addition, the high prevalence of oral cavity cancer in America contributes to this region's dominance over the global market. The American Cancer Society's most recent estimates for oral cavity and oropharyngeal cancers in the United States for 2022 indicate around 54,000 new cases of the oral cavity or oropharyngeal cancer and over 11 230 deaths from the oral cavity or oropharyngeal cancer. Thus, from the data mentioned above, it is anticipated that North America will dominate the global oral cavity cancer market during the forecast period.

Oral Cavity Cancer Companies & Competitive Landscape

Oral cavity cancer is highly concentrated among key players, such as Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Qilu Pharmaceutical Co., Ltd., Merck & Co., Inc., Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc. and Cipla Inc. These market players contribute to the growth of the global oral cavity cancer market through various strategies. For instance, in July 2021, Eli Lilly acquired a private biotech company Protomer Technologies, enhancing its product portfolio and market reach.

Eli Lilly company

Overview:

Eli Lilly company was founded in 1876 in Indianapolis, Indiana, U.S. and named after Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. It has its products sold in around 125 countries all around the world. Eli Lilly is pursuing bold advancements in medicine and pushing to close the gaps in healthcare inequality.

Product Portfolio:

The product portfolio of Eli Lilly company for Oral Cavity Cancer has Erbitux(R) (cetuximab): Erbitux is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of Head and Neck Cancer, Erbitux, in combination with radiation therapy, is indicated for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN).

The global oral cavity cancer market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.